Reactogenicity of the Messenger RNA SARS-CoV-2 Vaccines Associated With Immunogenicity in Patients With Autoimmune and Inflammatory Disease.

Monica M YangKimberly E TaylorDiana PaezAlex CarividiEmanuel DemissieNiti PawarAlia A El-QunniLily E McMorrow Rebecca E SchrieferKatherine HuangBaylee KinnettMichael KlebertAlem HaileJane A O'HalloranRachel M PrestiWooseob KimAli H EllebedyMatthew A CiorbaMichael A PaleyParakkal DeepakAlfred Hyoungju Kim Patricia P KatzMehrdad MatloubianMary NakamuraLianne S Gensler

Published in: Arthritis care & research (2022)

Patients with CID have a distinct reactogenicity profile following SARS-CoV-2 vaccination compared to controls. Furthermore, there is an association between increased reactogenicity and increased vaccine response. This finding may speak to the more variable immunogenicity in CID patients and may be an important indicator of vaccine response to the novel SARS-CoV-2 vaccines.

Keyphrases

sars cov
respiratory syndrome coronavirus
end stage renal disease
newly diagnosed
ejection fraction
oxidative stress
multiple sclerosis
patient reported outcomes
coronavirus disease